Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-COMPARE: upadacitinib vs placebo and adalimumab in methotrexate-inadequate responder rheumatoid arthritis
2022-501017-31-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Upadacitinib + methotrexate, Placebo + methotrexate and Adalimumab + methotrexate (3 arms). Primary endpoints: ACR20 response at Week 12 and DAS28-CRP clinical remission at Week 12. Planned start May 2016; status: authorised.
02
Drugs
upadacitinibadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-501017-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501017-31-00.